Breaking News
Get 40% Off 0
👀 Reveal Warren Buffett's stock picks that are beating the S&P 500 by +174.3% Get 40% Off
Close

Pharma Mar SAU (PHMR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
30.380 -0.020    -0.07%
13:51:26 - Delayed Data. Currency in EUR ( Disclaimer )
  • Volume: 13,054
  • Bid/Ask: 30.360 / 30.480
  • Day's Range: 30.220 - 30.760
Type:  Equity
Market:  Spain
ISIN:  ES0169501022 
Pharma Mar 30.380 -0.020 -0.07%

BME:PHMR Financials

 
See below for an overview of the Pharma Mar SAU financial reports. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track the BME:PHMR financials over time.

Pharma Mar, S.A. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was EUR 60.09 million compared to EUR 87.82 million a year ago. Revenue was EUR 117.64 million compared to EUR 145.53 million a year ago. Net income was EUR 7.96 million compared to EUR 43.37 million a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

PHMR Income Statement

Gross margin TTM 93.67%
Operating margin TTM 4.65%
Net Profit margin TTM 8.28%
Return on Investment TTM 2.67%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 37.45 46.21 33.98 54.94
Gross Profit 34.31 44.32 31.85 48.71
Operating Income -0.184 4.05 -2.57 1.37
Net Income 1.52 5.02 1.41 5.98

PHMR Balance Sheet

Quick Ratio MRQ 2.36
Current Ratio MRQ 3.01
LT Debt to Equity MRQ 13.03%
Total Debt to Equity MRQ 21.13%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 349.41 358.69 373.72 393.26
Total Liabilities 143.22 148.39 156.79 170.3
Total Equity 206.2 210.3 216.93 222.96

PHMR Cash Flow Statement

Cash Flow/Share TTM -0.71
Revenue/Share TTM 9.37
Operating Cash Flow  -8.06%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -6.98 -11.44 7.67 -2.07
Cash From Investing Activities 6.18 -20.34 -30.54 19.34
Cash From Financing Activities -6.42 -12.16 -7.24 3.16
Net Change in Cash -6.1 -43.64 -30.1 20.38
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PHMR Comments

Write your thoughts about Pharma Mar SAU
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jose Alcaraz
Jose Alcaraz Feb 09, 2021 17:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Facing 148 again in no time.
Massimo Calvo
Massimo Calvo Feb 09, 2021 17:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Where is your assertivity coming from, technically there is no signal it will hapoen
Marc Torras
Marc Torras Feb 07, 2021 21:27
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will go to the top again
Jose Alcaraz
Jose Alcaraz Feb 03, 2021 16:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Up!, Up!, Up!!
Jose Alcaraz
Jose Alcaraz Feb 01, 2021 19:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Next step: Phase III for coronavirus antiviral. 🚀🚀🚀
Arvinder Mann
ARVI Oct 30, 2020 8:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.gov.uk/government/news/government-invests-in-uk-developed-antibody-tests-from-uk-rapid-test-consortium
Razaq Shobande
Razaq Shobande Oct 29, 2020 13:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
very bullish
Harry Hanko
Harry Hanko Oct 20, 2020 15:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Anyone know what's happening with this at the moment?
Furquan Ali
Furquan Ali Oct 18, 2020 7:28
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I found this on trading 212
David Finlay
David Finlay Sep 30, 2020 7:26
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why cant I find this company on my trading platform?
minanath durge
minanath durge Sep 24, 2020 15:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
very bullish
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email